Search


	Podcast:		OncLive® On Air
	Episode:		9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
	Category:		Science & Medicine
	Duration:		00:31:42
	Publish Date:		2020-06-04 14:47:22
	Description:		In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.
	Total Play:		0